ATE172742T1 - Peptide mit wachstumshormonfreisetzender aktivität - Google Patents

Peptide mit wachstumshormonfreisetzender aktivität

Info

Publication number
ATE172742T1
ATE172742T1 AT92919262T AT92919262T ATE172742T1 AT E172742 T1 ATE172742 T1 AT E172742T1 AT 92919262 T AT92919262 T AT 92919262T AT 92919262 T AT92919262 T AT 92919262T AT E172742 T1 ATE172742 T1 AT E172742T1
Authority
AT
Austria
Prior art keywords
peptides
growth hormone
hormone releasing
releasing activity
activity
Prior art date
Application number
AT92919262T
Other languages
English (en)
Inventor
Cyril Y Bowers
David Coy
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE172742T1 publication Critical patent/ATE172742T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT92919262T 1991-08-22 1992-08-20 Peptide mit wachstumshormonfreisetzender aktivität ATE172742T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/748,350 US5663146A (en) 1991-08-22 1991-08-22 Polypeptide analogues having growth hormone releasing activity

Publications (1)

Publication Number Publication Date
ATE172742T1 true ATE172742T1 (de) 1998-11-15

Family

ID=25009088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919262T ATE172742T1 (de) 1991-08-22 1992-08-20 Peptide mit wachstumshormonfreisetzender aktivität

Country Status (26)

Country Link
US (2) US5663146A (de)
EP (1) EP0605484B1 (de)
JP (1) JP3179489B2 (de)
KR (1) KR100247212B1 (de)
CN (1) CN1035256C (de)
AT (1) ATE172742T1 (de)
AU (1) AU666673B2 (de)
BG (1) BG62655B1 (de)
BR (2) BR9206398A (de)
CA (1) CA2116120C (de)
CZ (1) CZ293281B6 (de)
DE (1) DE69227462T2 (de)
DK (1) DK0605484T3 (de)
ES (1) ES2124263T3 (de)
FI (2) FI120095B (de)
HU (1) HU223664B1 (de)
IL (1) IL102848A (de)
MX (1) MX9204861A (de)
NO (1) NO314695B1 (de)
NZ (1) NZ244034A (de)
PL (1) PL169562B1 (de)
RO (1) RO112507B1 (de)
RU (1) RU2126014C1 (de)
SK (1) SK282895B6 (de)
WO (1) WO1993004081A1 (de)
ZA (1) ZA926337B (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160786A1 (en) 1993-05-14 1994-11-24 James C. Marsters, Jr. Ras farnesyl transferase inhibitors
HU221092B1 (en) * 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
HU224345B1 (hu) * 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
BR9608909A (pt) * 1995-06-22 1999-03-02 Novo Nordisk As Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto
ATE231131T1 (de) * 1996-04-24 2003-02-15 Novo Nordisk As Verbindungen mit wachtumshormon freisetzenden eigenschaften
EP1005484A1 (de) 1997-06-20 2000-06-07 Novo Nordisk A/S Verbindungen mit wachstumshormon freisetzenden eigenschaften
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
AU766305B2 (en) 1998-01-16 2003-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1999039730A1 (fr) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (ja) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド 成長ホルモン分泌促進物質関連受容体および核酸
JP2002522058A (ja) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド イヌ成長ホルモン分泌促進物質受容体
US6468974B1 (en) 1998-08-14 2002-10-22 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7022677B1 (en) 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
AU759022B2 (en) * 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
KR20020047096A (ko) * 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
JP4691298B2 (ja) * 1999-10-12 2011-06-01 科研製薬株式会社 粉末吸入用製剤及びその製造方法
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
EA006484B1 (ru) 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
EP1450605B1 (de) * 2001-10-26 2011-12-07 Baylor College Of Medicine Zusammensetzung für die änderung der knocheneigenschaften bei einem probanden
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
MY142457A (en) * 2001-12-11 2010-11-30 Advisys Inc Plasmid mediated supplementation for treating chronically ill subjects
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
TW200307749A (en) * 2002-02-07 2003-12-16 Baylor College Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
ES2271557T3 (es) * 2002-04-09 2007-04-16 Eli Lilly And Company Secretagogos dipeptidicos de la hormona del crecimiento.
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003259340A1 (en) 2002-08-23 2004-03-11 Gestion Univalor Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
WO2004067719A2 (en) * 2003-01-28 2004-08-12 Advisys, Inc. Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005016964A2 (en) * 2003-08-04 2005-02-24 Advisys, Inc. Canine specific growth hormone releasing hormone
WO2005041998A1 (en) 2003-10-02 2005-05-12 Ali Sadat M Peptide for promoting healing of fractures
ATE467417T1 (de) * 2003-12-31 2010-05-15 VGX Pharmaceuticals LLC Reduzierung von arthritis und lahmheit bei personen unter supllement von wachstumshormon freisetzendem hormon (ghrh)
EP1713828B1 (de) * 2004-01-20 2011-04-27 VGX Pharmaceuticals, LLC Erhöhte sekretion/retention von wachstumshormonfreisetzendem hormon (ghrh) aus muskelzellen durch speziesspezifisches signalpeptid
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
ATE413890T1 (de) * 2004-07-23 2008-11-15 Advisys Inc Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort
CA2576915A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2006116401A1 (en) 2005-04-28 2006-11-02 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
KR101388087B1 (ko) 2005-08-31 2014-04-25 유니버시티 오브 테네시 리서치 파운데이션 선택적 안드로겐 수용체 조절제를 이용한 신장 질환, 화상,부상 및 척수 손상의 치료 방법
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
KR101410453B1 (ko) 2006-08-02 2014-06-27 싸이토키네틱스, 인코포레이티드 소정의 화학 물질, 조성물 및 방법
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN107007581A (zh) 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
EP2155769B1 (de) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Schutz gegen gewebedegeneration
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
AU2013203600C1 (en) 2012-07-13 2016-11-24 University Of Tennessee Research Foundation A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
WO2014168973A2 (en) 2013-04-08 2014-10-16 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3148587B1 (de) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrilderivate als selektive androgenrezeptormodulatoren
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3990447A1 (de) 2019-06-27 2022-05-04 Cytokinetics, Inc. Polymorphe von 1-(2-(((trans)-3-fluor-1-(3-fluorpyridin-2-yl)butyl)methyl)amino) pyrimidin-5-yl)-1h-pyrrol-3-carboxamid
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
WO1983002272A1 (en) * 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4410513A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
ATE113607T1 (de) * 1988-01-28 1994-11-15 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
JPH03502329A (ja) * 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
WO1989010933A1 (en) * 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
WO1992001709A1 (en) 1990-07-24 1992-02-06 Eastman Kodak Company Process for synthesizing peptides

Also Published As

Publication number Publication date
DK0605484T3 (da) 1999-07-05
FI120691B (fi) 2010-01-29
US5776901A (en) 1998-07-07
AU666673B2 (en) 1996-02-22
WO1993004081A1 (en) 1993-03-04
BR9206398A (pt) 1994-12-27
AU2541692A (en) 1993-03-16
EP0605484A1 (de) 1994-07-13
DE69227462D1 (de) 1998-12-03
CN1073684A (zh) 1993-06-30
CA2116120C (en) 2002-12-03
IL102848A (en) 1998-04-05
NO940592L (no) 1994-04-14
BR1100309A (pt) 2000-08-01
CA2116120A1 (en) 1993-02-23
JPH07507039A (ja) 1995-08-03
FI120095B (fi) 2009-06-30
NO314695B1 (no) 2003-05-05
NZ244034A (en) 1995-08-28
FI940807A (fi) 1994-02-21
BG62655B1 (bg) 2000-04-28
CN1035256C (zh) 1997-06-25
RO112507B1 (ro) 1997-10-30
ES2124263T3 (es) 1999-02-01
FI20050467A (fi) 2005-05-02
HUT69178A (en) 1995-08-28
HU9400495D0 (en) 1994-05-30
DE69227462T2 (de) 1999-04-08
EP0605484B1 (de) 1998-10-28
US5663146A (en) 1997-09-02
BG98489A (bg) 1995-02-28
JP3179489B2 (ja) 2001-06-25
CZ40094A3 (en) 1994-11-16
IL102848A0 (en) 1993-01-31
ZA926337B (en) 1993-04-22
RU2126014C1 (ru) 1999-02-10
KR100247212B1 (ko) 2000-03-15
PL169562B1 (pl) 1996-08-30
SK20494A3 (en) 1994-10-05
CZ293281B6 (cs) 2004-03-17
HU223664B1 (hu) 2004-11-29
MX9204861A (es) 1994-06-30
FI940807A0 (fi) 1994-02-21
NO940592D0 (no) 1994-02-21
SK282895B6 (sk) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE172742T1 (de) Peptide mit wachstumshormonfreisetzender aktivität
DE68922602D1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
DE3883789T2 (de) Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
RU94016393A (ru) Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения
DE3853384T2 (de) Peptid.
MX9203328A (es) Complejo de interferon de zinc-protamina-alfa.
NO870441D0 (no) Farmasoeytiske preparatformer for stabilisering av alfa- interferon.
LV11985A (lv) Noteiktu cistina atvasinajumu farmakologiska izmantosana
ES450439A1 (es) Un metodo para preparar un peptido de somatostina.
DE68909409D1 (de) Heilmitteldosierung zur verabreichung an fische.
DE69105207D1 (de) Peptidverbindungen mit wachstumshormonfreisetzender aktivität.
IT8520712A0 (it) Formulazioni farmaceutiche per stimolare la liberazione di ormone somatotropo.
NO164479C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptidforbindelser.
ATE93865T1 (de) Polypeptidverbindungen mit wachstumshormonfreisetzender aktivitaet.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification